Jimenez, Eulalia
Astbury, Carol
Albayaty, Muna
Wählby-Hamrén, Ulrika
Seoane, Beatriz
Villarroel, Cristina
Pujol, Helena
Bermejo, Maria Jesus
Aggarwal, Ajay
Psallidas, Ioannis
Funding for this research was provided by:
AstraZeneca
Article History
Received: 12 June 2020
Accepted: 24 July 2020
First Online: 9 September 2020
Ethics approval and consent to participate
: The study protocol and consent form were reviewed and approved by an Independent Ethics Committee (NRES Committee – Cambridgeshire and Hertfordshire, Health Research Authority, Nottingham, UK; Reference No 15/EE/0329) and the study was performed in accordance with the Declaration of Helskini, the International Conference on Harmonisation/Good Clinical Practice and the AstraZeneca bioethics policy. All patients provided written informed consent before taking part in the study.
: Not applicable.
: EJ, CA, UW-H, BS, and IP are employees of AstraZeneca and may own stock or stock options. MA is an employee of PAREXEL. AstraZeneca contracted PAREXEL for the conduct of this study. CV, HP, MJB, and AA were employees of AstraZeneca at the time the study was conducted. CV is a current employee of PAREXEL. HP is a current employee of Allergy Therapeutics, MJB is a current employee of InsudPharma, and AA is a current employee of Eloxx Pharmaceuticals.